Randomized, Double-Blind, Plac.-Controlled Clinical Study to Compare the Efficacy of FP-101 60mg b.i.d. vs. Placebo for the Treatment of Moderate-to-Severe Hot Flashes in Peri- and Post-menopausal Women Over a Period of 1-Week.
Latest Information Update: 30 Oct 2023
At a glance
- Drugs FP-101 (Primary)
- Indications Hot flashes
- Focus Proof of concept; Therapeutic Use
- Sponsors Fervent Pharmaceuticals
Most Recent Events
- 24 Oct 2023 Status changed from active, no longer recruiting to completed.
- 24 May 2023 Status changed from recruiting to active, no longer recruiting.
- 21 Feb 2023 Planned End Date changed from 31 Dec 2022 to 30 Sep 2023.